Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tango Therapeutics, Inc. (TNGX : NSDQ)

• Company Description    Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass. Number of Employees: 91

• Price / Volume Information    Yesterday's Closing Price: $5.41 Daily Weekly Monthly 20 Day Moving Average: 220,928 shares Shares Outstanding: 87.90 (millions) Market Capitalization: $475.52 (millions) Beta: 0.58 52 Week High: $17.97 52 Week Low: $4.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.50% -17.21% 12 Week -40.15% -34.20% Year To Date -50.55% -39.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 BINNEY ST SUITE 700 - CAMBRIDGE,MA 02142 USA ph: 857-320-4900 fax: - None http://www.tangotx.com

• General Corporate Information    Officers Barbara Weber - President and Chief Executive Officer; Director Alexis Borisy - Chairman Daniella Beckman - Chief Financial Officer Lesley Ann Calhoun - Director Aaron Davis - Director Peer Information Tango Therapeutics, Inc. (CORR.) Tango Therapeutics, Inc. (RSPI) Tango Therapeutics, Inc. (CGXP) Tango Therapeutics, Inc. (BGEN) Tango Therapeutics, Inc. (GTBP) Tango Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87583X109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 87.90 Most Recent Split Date: (:1) Beta: 0.58 Market Capitalization: $475.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.48 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -16.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.73% ROE 03/31/22 - -26.12 12/31/21 - -23.68 09/30/21 - - ROA 03/31/22 - -16.20 12/31/21 - -12.48 09/30/21 - - Current Ratio 03/31/22 - 11.75 12/31/21 - 12.10 09/30/21 - 12.30 Quick Ratio 03/31/22 - 11.75 12/31/21 - 12.10 09/30/21 - 12.30 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -389.46 12/31/21 - -156.43 09/30/21 - - Book Value 03/31/22 - 3.64 12/31/21 - 3.94 09/30/21 - 4.18 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©